Showing items 546-570 of 2549 (102 Page(s) Totally)
<< < 17 18 19 20 21 22 23 24 25 26 > >>
View [10|25|50] records per page
| 臺大學術典藏 |
2021-07-15T02:20:11Z |
Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate
|
Wen W.-H.; HUEY-LING CHEN; Shih T.T.-F.; Wu J.-F.; Ni Y.-H.; Lee C.-N.; Zhao L.-L.; Lai M.-W.; Mu S.-C.; Tung Y.-C.; Hsu H.-Y.; Chang M.-H.; Shyu M.K.; Hwa H.L.; Su Y.N.; Shih J.C.; Chao K.H.; Chiu Y.C.; Chang K.C.; Liu C.J.; Su T.H.; Chen D.S.; Chen S.M.; Lin C.C.; Lin P.Y.; Yang W.R.; Hu J.J.; Yang C.K.; Chang Y.K.; Chen K.H.; Lin H.H.; Lin Y.H.; Chen H.J.; Pan H.S.; Lau B.H.; Lee C.L.; Cheng P.J.; Chang Y.L.; Chiueh H.Y.; Wang T.H.; Hsu J.J.; Lo L.M.; Hsieh C.L.; Cheng S.W.; Tsai M.S.; Lin L.H.; She B.Q.; Peng F.S.; Lin Y.C.; Chen C.P.; Huang J.P.; Yeung C.Y.; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study); HUEY-LING CHEN |
| 臺大學術典藏 |
2021-07-13T06:04:37Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
LEE JIH-HSIANG; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:36Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C.; LEE JIH-HSIANG; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:36Z |
Profile of the therascreen? EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer
|
Hsiue E.H.-C.; LEE JIH-HSIANG; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:36Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; LEE JIH-HSIANG; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:35Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C.; Lin C.-C.; LEE JIH-HSIANG; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:34Z |
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
|
Liao B.-C.; Lin C.-C.; LEE JIH-HSIANG; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:33Z |
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
|
Lin C.-C.; Shih J.-Y.; Yu C.-J.; Ho C.-C.; Liao W.-Y.; LEE JIH-HSIANG; Tsai T.-H.; Su K.-Y.; Hsieh M.-S.; Chang Y.-L.; Bai Y.-Y.; Huang D.D.-R.; Thress K.S.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:33Z |
Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan
|
Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; Su K.-Y.; Chang Y.-L.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J. |
| 臺大學術典藏 |
2021-07-13T06:04:32Z |
Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non�VSmall-cell Lung Cancer Patients
|
Wu T.-H.; Hsiue E.H.-C.; LEE JIH-HSIANG; Lin C.-C.; Liao W.-Y.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-13T06:04:32Z |
Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
|
Liao B.-C.; Bai Y.-Y.; LEE JIH-HSIANG; Lin C.-C.; Lin S.-Y.; Lee Y.-F.; Ho C.-C.; Shih J.-Y.; Chang Y.-C.; Yu C.-J.; Chih-Hsin Yang J.; Yang P.-C. |
| 臺大學術典藏 |
2021-07-13T06:04:30Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-07-13T06:04:29Z |
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
|
LEE JIH-HSIANG; Chen T.W.-W.; Hsu C.-H.; Yen Y.-H.; Yang J.C.-H.; Cheng A.-L.; Sasaki S.-I.; Chiu L.Y.; Sugihara M.; Ishizuka T.; Oguma T.; Tajima N.; Lin C.-C. |
| 臺大學術典藏 |
2021-07-13T06:04:28Z |
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours
|
de Bono J.; Lin C.-C.; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; LEE JIH-HSIANG; Hsu C.-H.; Yang J.C.-H.; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-07-13T06:04:27Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; LEE JIH-HSIANG; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2021-07-12T08:46:26Z |
EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
|
HSIANG-FONG KAO; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2021-07-08T01:23:52Z |
Persistent endodontic lesion due to complex cementodentinal tears in a maxillary central incisor-a case report
|
Tai T.-F.; Chiang C.-P.; Lin C.-P.; Lin C.-C.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:51Z |
Horizontal/oblique root fractures in the palatal root of maxillary molars with associated periodontal destruction: Case reports
|
Lin C.C.; Tsai Y.L.; Li U.M.; Chang Y.C.; Lin C.P.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:51Z |
Transforming Growth Factor β2 Regulates Growth and Differentiation of Pulp Cells via ALK5/Smad2/3
|
Tai T.-F.; Chan C.-P.; Lin C.-C.; Chen L.-I.; JIIANG-HUEI JENG; Chang M.-C. |
| 臺大學術典藏 |
2021-07-08T01:23:49Z |
The effect of BisGMA on cyclooxygenase-2 expression, PGE2 production and cytotoxicity via reactive oxygen species- and MEK/ERK-dependent and -independent pathways
|
Chang M.-C.; Lin L.-D.; Chan C.-P.; Chang H.-H.; Chen L.-I.; Lin H.-J.; Yeh H.-W.; Tseng W.-Y.; Lin P.-S.; Lin C.-C.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:49Z |
Prostaglandin F2α-Induced Interleukin-8 Production in Human Dental Pulp Cells Is Associated With MEK/ERK Signaling
|
Chang M.-C.; Chang H.-H.; Lee M.-Y.; Lin C.-C.; Yeh H.-W.; Yang T.-T.; Lin P.-S.; Tseng W.-Y.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:49Z |
Areca nut-induced micronuclei and cytokinesis failure in Chinese hamsterovary cells is related to reactive oxygen species production and actin filament deregulation
|
Lin C.-C.; Chang M.-C.; Chang H.-H.; Wang T.-M.; Tseng W.-Y.; Tai T.-F.; Yeh H.-W.; Yang T.-T.; Hahn L.-J.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:48Z |
Comparative cytotoxicity of five current dentin bonding agents: Role of cell cycle deregulation
|
Yeh H.-W.; Chang M.-C.; Lin C.-P.; Tseng W.-Y.; Chang H.-H.; Wang T.-M.; Chen Y.-J.; Lin C.-C.; Yang T.-T.; Lin L.-D.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:44Z |
Antiplatelet effect by p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A 2 production
|
Chang M.-C.; Wang T.-M.; Yeung S.-Y.; Jeng P.-Y.; Liao C.-H.; Lin T.-Y.; Lin C.-C.; Lin B.-R.; JIIANG-HUEI JENG |
| 臺大學術典藏 |
2021-07-08T01:23:44Z |
Cemental tear: Clinical characteristics and its predisposing factors
|
Lin H.-J.; Chan C.-P.; Yang C.-Y.; Wu C.-T.; Tsai Y.-L.; Huang C.-C.; Yang K.-D.; Lin C.-C.; Chang S.-H.; JIIANG-HUEI JENG |
Showing items 546-570 of 2549 (102 Page(s) Totally)
<< < 17 18 19 20 21 22 23 24 25 26 > >>
View [10|25|50] records per page
